These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 30593615)

  • 1. Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus.
    Li DK; Chung RT
    Methods Mol Biol; 2019; 1911():3-32. PubMed ID: 30593615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
    McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b.
    Kanda T; Nirei K; Matsumoto N; Higuchi T; Nakamura H; Yamagami H; Matsuoka S; Moriyama M
    World J Gastroenterol; 2017 Dec; 23(46):8120-8127. PubMed ID: 29290649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K.
    Martínez AP; Culasso ACA; Pérez PS; Romano V; Campos RH; Ridruejo E; García G; Di Lello FA
    Virus Res; 2017 Aug; 240():140-146. PubMed ID: 28837817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.
    Bagaglio S; Uberti-Foppa C; Morsica G
    Drugs; 2017 Jul; 77(10):1043-1055. PubMed ID: 28497432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome.
    Bagaglio S; Hasson H; Peano L; Vercesi R; Messina E; Galli A; Foppa CU; Morsica G
    Viruses; 2020 Feb; 12(3):. PubMed ID: 32121164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection.
    Esposito I; Marciano S; Haddad L; Galdame O; Franco A; Gadano A; Flichman D; Trinks J
    Viruses; 2018 Dec; 11(1):. PubMed ID: 30577623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals.
    Perpiñán E; Caro-Pérez N; García-González N; Gregori J; González P; Bartres C; Soria ME; Perales C; Lens S; Mariño Z; Londoño MC; Ariza X; Koutsoudakis G; Quer J; González-Candelas F; Forns X; Pérez-Del-Pulgar S
    J Viral Hepat; 2018 Dec; 25(12):1515-1525. PubMed ID: 30141252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of naturally occurring amino acid substitutions associated with resistance to hepatitis C virus NS3/NS4A protease inhibitors in São Paulo state.
    Moreira RC; de Torres Santos AP; Lisboa-Neto G; Mendes-Corrêa MCJ; Lemos MF; Malta FM; Santana RAF; Dastoli GTF; de Castro VFD; Pinho JRR
    Arch Virol; 2018 Oct; 163(10):2757-2764. PubMed ID: 29961118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing.
    Nguyen T; Akhavan S; Caby F; Bonyhay L; Larrouy L; Gervais A; Lebray P; Poynard T; Calmus Y; Simon A; Valantin MA; Calvez V; Marcelin AG; Todesco E
    Int J Antimicrob Agents; 2019 Jan; 53(1):80-83. PubMed ID: 30236959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction and characterization of Genotype-3 hepatitis C virus replicon revealed critical genotype-3-specific polymorphism for drug resistance and viral fitness.
    Guo M; Lu J; Gan T; Xiang X; Xu Y; Xie Q; Zhong J
    Antiviral Res; 2019 Nov; 171():104612. PubMed ID: 31542377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compartmentalization of Resistance-Associated Substitutions in HIV/HCV-Infected Patients: Possible Correlation with Infecting HCV Genotype.
    Morsica G; Vercesi R; Hasson H; Messina E; Uberti-Foppa C; Bagaglio S
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenge to overcome: Nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus.
    Sato K; Uraoka T
    World J Gastroenterol; 2018 Oct; 24(38):4304-4310. PubMed ID: 30344416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral resistance and direct-acting antiviral agents for HCV.
    Aloia AL; Locarnini S; Beard MR
    Antivir Ther; 2012; 17(6 Pt B):1147-62. PubMed ID: 23188771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of RASs /RVs in the Current Management of HCV.
    Malandris K; Kalopitas G; Theocharidou E; Germanidis G
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.
    Eltahla AA; Rodrigo C; Betz-Stablein B; Grebely J; Applegate T; Luciani F; Schinkel J; Dore GJ; Page K; Bruneau J; Morris MD; Cox AL; Kim AY; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Lloyd AR; Bull RA;
    J Viral Hepat; 2017 Jan; 24(1):37-42. PubMed ID: 27666440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of pre-treatment hepatitis C virus NS5A resistance associated amino-acid substitutions in genotype 1A infected patients in Scotland.
    Bradley-Stewart A; Goldstein E; MacLean A; Gunson R
    J Clin Virol; 2018 Apr; 101():44-46. PubMed ID: 29414187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HCV Replicon Systems: Workhorses of Drug Discovery and Resistance.
    Khan S; Soni S; Veerapu NS
    Front Cell Infect Microbiol; 2020; 10():325. PubMed ID: 32714881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to DAAs: When to Look and When It Matters.
    Wyles DL
    Curr HIV/AIDS Rep; 2017 Dec; 14(6):229-237. PubMed ID: 29116550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives.
    Harrington PR; Komatsu TE; Deming DJ; Donaldson EF; O'Rear JJ; Naeger LK
    Hepatology; 2018 Jun; 67(6):2430-2448. PubMed ID: 29194682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.